Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 1;10(1):54-62.
doi: 10.1001/jamaoncol.2023.5098.

Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study

Affiliations

Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study

Jesper Nors et al. JAMA Oncol. .

Abstract

Importance: Management of colorectal cancer (CRC) has been updated continuously over the past 2 decades. While the combination of these initiatives has had implications for improved survival, the implications for rates of recurrence remain unexplored.

Objective: To ascertain the rates of recurrence and describe time to recurrence within 5 years of surgery with curative intent for stages I to III CRC.

Design, setting, and participants: This cohort study used the Danish Colorectal Cancer Group Database to identify patients with Union for International Cancer Control (UICC) stages I to III CRC who underwent primary surgery between January 1, 2004, and December 31, 2019. They were followed up until recurrence (event), death (competing event), diagnosis of a second cancer (competing event), emigration (censoring event), 5 years postoperatively (censoring event), or January 1, 2023 (censoring event), whichever came first. Recurrence status was ascertained through individual-level linked data from the Danish Cancer Registry, Danish National Patient Registry, and Danish Pathology Registry using a validated algorithm. Data were analyzed from January 1 to August 8, 2023.

Exposure: Primary surgery performed during 3 calendar periods (2004-2008, 2009-2013, and 2014-2019) stratified by tumor site (colon or rectum) and UICC stage (I, II, and III).

Main outcomes and measures: Stage-specific 5-year recurrence reported as the cumulative incidence function (CIF) of recurrence, the association between calendar period of primary surgery and recurrence risk reported as subdistribution hazard ratios (sHRs), and the time from surgery to recurrence.

Results: Of the 34 166 patients with UICC stages I to III CRC (median [IQR] age, 70 [62-77] years); 18 552 males [54.3%]) included in the study, 7027 developed recurrence within 5 years after the primary surgery. For colon cancer, the 5-year CIF of recurrence decreased over the 3 calendar periods from 16.3% to 6.8% for UICC stage I, from 21.9% to 11.6% for UICC stage II, and from 35.3% to 24.6% for UICC stage III colon cancer. For rectal cancer, the 5-year CIF decreased over the 3 periods from 19.9% to 9.5% for stage I, from 25.8% to 18.4% for stage II, and from 38.7% to 28.8% for stage III disease. Patients with stage III disease had a shorter time from surgery to recurrence compared with those with stage I disease (time ratio stage III vs stage I = 0.30; 95% CI, 0.28-0.32). Cancers detected through screening were associated with lower stage-adjusted risks of recurrence (sHR, 0.81; 95% CI, 0.73-0.91) compared with cancers not detected through screening.

Conclusions and relevance: In this cohort of patients with CRC, the risk of recurrence decreased in patients with stages I to III disease during the study period. Cancer detection by screening was associated with an even lower risk of recurrence. Time to recurrence differed according to UICC stage. Because the risk of recurrence was so low in selected patient groups, future research is warranted to explore risk-stratified surveillance protocols in patients with CRC.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Prof Andersen reported receiving grants from the Novo Nordisk Foundation, Innovation Fund Denmark, and Danish Cancer Society during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Cumulative Incidence Function Curves for Colorectal Cancer Recurrence Stratified by Tumor Site and Compared by Calendar Period of Curative Surgery
Curves were constructed using the Aalen-Johansen estimator. Patients were right-censored at emigration, 5 years of follow-up, or on January 1, 2023, whichever came first. sHR indicates subdistribution hazard ratio calculated using Fine-Gray regression adjusted for sex, age, comorbidities, and Union for International Cancer Control stage.
Figure 2.
Figure 2.. Time From Surgery to Colorectal Cancer Recurrence by Union for International Cancer Control (UICC) Stage
Vertical dashed lines represent median time from curative surgery to recurrence. Shaded areas represent time points of surveillance imaging at 12 and 36 months after surgery (as per Danish guidelines since 2009).
Figure 3.
Figure 3.. Cumulative Incidence Function Curves for Colorectal Cancer Recurrence According to Cancer Detection Method (Screening or Not Screening) Stratified by Union for International Cancer Control (UICC) Stage
Curves were constructed using the Aalen-Johansen estimator. Patients were right-censored at emigration, 5 years of follow-up, or on January 1, 2023, whichever came first. sHR indicates subdistribution hazard ratio calculated using Fine-Gray regression adjusted for sex, age, comorbidities, and UICC stage.

Comment in

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 - DOI - PubMed
    1. Sargent D, Sobrero A, Grothey A, et al. . Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872-877. doi:10.1200/JCO.2008.19.5362 - DOI - PMC - PubMed
    1. Shah MA, Renfro LA, Allegra CJ, et al. . Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016;34(8):843-853. doi:10.1200/JCO.2015.63.0558 - DOI - PMC - PubMed
    1. Iversen LH, Green A, Ingeholm P, Østerlind K, Gögenur I. Improved survival of colorectal cancer in Denmark during 2001-2012—the efforts of several national initiatives. Acta Oncol. 2016;55(suppl 2):10-23. doi:10.3109/0284186X.2015.1131331 - DOI - PubMed
    1. Olesen F, Hansen RP, Vedsted P. Delay in diagnosis: the experience in Denmark. Br J Cancer. 2009;101(suppl 2):S5-S8. doi:10.1038/sj.bjc.6605383 - DOI - PMC - PubMed

Publication types